This database contains 14 studies, archived under the term: "The Lancet. Neurology"
Click here to filter this large number of results.
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, Bengt,
Andreasen, Niels,
Minthon, Lennart,
Floesser, Annette,
Imbert, Georges,
Dumortier, Thomas,
Maguire, R. Paul,
Blennow, Kaj,
Lundmark, Joens,
Staufenbiel, Matthias,
Orgogozo, Jean-Marc,
Graf, Ana
Background: Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer’s disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer’s disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.; Methods: We did a phase […]
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
de Yebenes, Justo Garcia,
Landwehrmeyer, Bernhard,
Squitieri, Ferdinando,
Reilmann, Ralf,
Rosser, Anne,
Barker, Roger A,
Saft, Carsten,
Magnet, Markus K.,
Sword, Alastair,
Rembratt, Åsa,
Tedroff, Joakim
Background: Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary motor function. We aimed to assess further the […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial
Vellas, Bruno,
Coley, Nicola,
Ousset, Pierre-Jean,
Berrut, Gilles,
Dartigues, Jean-François,
Dubois, Bruno,
Grandjean, Hélène,
Pasquier, Florence,
Piette, François,
Robert, Philippe,
Touchon, Jacques,
Garnier, Philippe,
Mathiex-Fortunet, Hélène,
Andrieu, Sandrine
Background: Prevention strategies are urgently needed to tackle the growing burden of Alzheimer’s disease. We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer’s disease in elderly adults with memory complaints.; Methods: In the randomised, parallel-group, double-blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged […]
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study
Shatunov, Aleksey,
Mok, Kin,
Newhouse, Stephen,
Weale, Michael E,
Smith, Bradley,
Vance, Caroline,
Johnson, Lauren,
Veldink, Jan H,
van Es, Michael A,
van den Berg, Leonard H.,
Robberecht, Wim,
Van Damme, Philip,
Hardiman, Orla,
Farmer, Anne E,
Lewis, Cathryn M,
Butler, Amy W,
Abel, Olubunmi,
Andersen, Peter M,
Fogh, Isabella,
Silani, Vincenzo,
Chiò, Adriano,
Traynor, Bryan J,
Melki, Judith,
Meininger, Vincent,
Landers, John E,
McGuffin, Peter,
Glass, Jonathan D,
Pall, Hardev,
Leigh, P Nigel,
Hardy, John,
Brown, Robert H,
Powell, John F,
Orrell, Richard W,
Morrison, Karen E,
Shaw, Pamela J,
Shaw, Christopher E,
Al-Chalabi, Ammar
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of motor neurons that results in progressive weakness and death from respiratory failure, commonly within about 3 years. Previous studies have shown association of a locus on chromosome 9p with ALS and linkage with ALS-frontotemporal dementia. We aimed to test whether this genomic region is also […]
Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study
Paulsen, Jane S.,
Long, Jeffrey D,
Ross, Christopher A,
Harrington, Deborah L,
Erwin, Cheryl J,
Williams, Janet K,
Westervelt, Holly James,
Johnson, Hans J,
Aylward, Elizabeth H,
Zhang, Ying,
Bockholt, H Jeremy,
Barker, Roger A
Background: Although the association between cytosine-adenine-guanine (CAG) repeat length and age at onset of Huntington’s disease is well known, improved prediction of onset would be advantageous for clinical trial design and prognostic counselling. We compared various measures for tracking progression and predicting conversion to manifest Huntington’s disease.; Methods: In this prospective observational study, we assessed […]
Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: A phase 2, randomised, double-blind, placebo-controlled trial
Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
Haïk, Stéphane,
Marcon, Gabriella,
Mallet, Alain,
Tettamanti, Mauro,
Welaratne, Arlette,
Giaccone, Giorgio,
Azimi, Shohreh,
Pietrini, Vladimiro,
Fabreguettes, Jean-Roch,
Imperiale, Daniele,
Cesaro, Pierre,
Buffa, Carlo,
Aucan, Christophe,
Lucca, Ugo,
Peckeu, Laurène,
Suardi, Silvia,
Tranchant, Christine,
Zerr, Inga,
Houillier, Caroline,
Redaelli, Veronica,
Vespignani, Hervé,
Campanella, Angela,
Sellal, François,
Krasnianski, Anna,
Seilhean, Danielle,
Heinemann, Uta,
Sedel, Frédéric,
Canovi, Mara,
Gobbi, Marco,
Di Fede, Giuseppe,
Laplanche, Jean-Louis,
Pocchiari, Maurizio,
Salmona, Mario,
Forloni, Gianluigi,
Brandel, Jean-Philippe,
Tagliavini, Fabrizio
Background: Creutzfeldt-Jakob disease (CJD) is a fatal, untreatable prion encephalopathy. Previous studies showed that doxycycline is effective in in-vitro and in-vivo models of disease, and patients with CJD who received compassionate treatment with doxycycline showed increased survival time compared with historical series. We therefore did a randomised, double-blind study of doxycycline versus placebo in CJD.; […]